BETA
Irvine-based medical aesthetics company marketing RF microneedling and picosecond laser platforms, with additional energy-based systems in development.
Boston Aesthetics develops and commercializes energy-based aesthetic technologies for physicians and practices. Founded in Boston in 2024, it established its global headquarters in Irvine, California in 2025.
Its current professional lineup features ZenTite, an RF microneedling and monopolar RF platform, and Boston PICO, a picosecond Nd:YAG laser. FDA records also identify additional cleared systems whose current launch status is not established in the reviewed catalog. The company works with Peninsula Medical Group on engineering, manufacturing and delivery.
Brandon Nye became CEO in April 2026 as the company expanded its commercial organization. Announced development programs include HIFU, further laser platforms and Project Beacon. Current revenue, financing amounts and installed-base totals remain unconfirmed; its published 2032 commercial goals are not current results.
ZenTite/Unicorn+ and Boston PICO have Class II clearances. The later ZenTite decision is filed by Shenzhen Peninsula Medical Group. Device labeling, commercial claims and manufacturer relationships are recorded separately. [9][11][12][10][21][22][23][24][28]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [30][31]
Latest recorded source review: 2026-10-20.
Documented commercial product families.
Professional RF platform with invasive microneedling and non-invasive handpieces. Manufacturer claims about comfort and tightening require separate clinical appraisal. [24][5][4][9][11]
FDA-clearedIn market according to current company portfolio.
1064nm and 532nm laser with zoom and fractional handpieces. [26][12]
FDA-clearedIn market according to current company portfolio.
UV-K, UV-X, UV-Y and UV-Z systems in FDA records. The site’s Zen 308 navigation link was unavailable, so model equivalence is not assumed. [10]
Commercial availability not establishedFDA cleared; current branded availability and home-use configuration not established.
Cleared RF platform appearing in FDA records; current launch and catalog mapping remain unresolved. [13]
Commercial availability not establishedMarketing authorization verified; commercial launch not established.
Separate cleared laser system; not automatically merged with the current 1064/532nm Boston PICO. [14]
Commercial availability not establishedMarketing authorization verified; current commercial availability not established.
Cleared laser for dermatological coagulation, resurfacing and ablation. Mapping to the company’s unnamed pipeline remains unconfirmed. [15]
Commercial availability not establishedMarketing authorization verified; launch not established.
HIFU tightening/lifting, rejuvenation and resurfacing lasers, and Project Beacon are announced programs. Their relationship to iFace, Pico755 and Boston 2910 is not confirmed. A cited 21-person split-face study supports further clinical review but does not establish all current configurations or marketing claims. [2][4][5]
HIFU tightening/lifting, rejuvenation and resurfacing lasers, plus an undisclosed all-in-one Project Beacon platform. [2]
Investigational / in developmentCompany identifies these as development or forthcoming programs.
K253245 authorized a resurfacing laser; clearance is recorded separately from launch status. [15]
Company appointed the former InMode sales executive to lead commercial expansion; release also describes Peninsula investment and manufacturing support without disclosing a financing amount. [3]
FDA issued K251981 and K254290. The ZenTite applicant is Shenzhen Peninsula Medical Group. [11][12]
K244022 covers four UV system models; current branded availability requires confirmation. [10]
K241832 authorized the RF family underlying the ZenTite platform. [9]
Company reports establishing its Irvine, California headquarters in 2025. [25]
Accessed 10/20/2026